Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.

Press Release - Provectus Pharmaceuticals, Inc. (PVCT-OCT: BB)

We have solved the essential problem that other scientists and companies have not been able to solve; that is to make a cancer specific drug. We have found out how to make it simply, pragmatically and inexpensively; namely, to build it and make a very safe molecule. - Dr. H. Craig Dees, Ph.D. (PVCT) (Interview published April 12, 2007)

The Most Powerful Name In Corporate News and Information.

CURRENT ISSUE  |  COVER ARCHIVES  |   INDEX   |  CONTACT  |  FINANCIALS  |  MARKETING SERVICES   |   HOME PAGE


CEOCFO
-
Members Login

Become A Member!



 

Provectus News

PV-10 for Melanoma Clinical Trial Gaining Media Attention
Monday June 14, 2010

The positive PV-10 for melanoma Phase 2 clinical trial data presented at ASCO 2010, including encouraging data on visceral metastases, has gained the attention of several prominent medical trade outlets. The following articles are available for viewing online:

Doctor's Guide Channels
"Chemoablation of Metastatic Melanoma with Rose Bengal Shows Robust Response: Presented at ASCO"
http://www.docguide.com/news/content.nsf/news/852576140048867C8525773D00641042

Medical News Today
"Metastatic Melanoma PV-10 Trial Results Encouraging Says Drug Company"
http://www.medicalnewstoday.com/articles/153024.php

Skin & Aging
"Provectus Announces New Positive Data from Phase II Trial of PV-10 for Metastatic Melanoma"
http://www.skinandaging.com/content/provectus-announces-new-positive-data-phase-ii-trial-pv-10-metastatic-melanoma




    

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.